3 completed, 1 recruiting, 1 terminated. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Candidiasis, Chronic Mucocutaneous: new trials by email Literature Review of Candidiasis, Chronic Mucocutaneous trials Research Report on Candidiasis, Chronic Mucocutaneous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Characterization of the Fungal Origins in the Autoimmune Polyendocrinopathy of Type 1 Compared With the Autoimmune Polyendocrinopathies of Type 2 Polyendocrinopathies, Autoimmune | Terminated | University Hospital, Lille | 7 | 2021-04-23 | 2026-05-22 | |
| Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Ibrexafungerp - Invasive Candidiasis, Mucocutaneous Candidiasis | Phase 3 | Completed | Scynexis, Inc. | 233 | 2017-04-01 | 2024-11-20 |
| CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis Amphotericin B - Candidiasis, Chronic Mucocutaneous | Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 4 | 2016-09-27 | 2024-08-07 |
| Rituximab for Anti-cytokine Autoantibody-Associated Diseases Rituximab - Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 7 | 2014-04-29 | 2026-10-16 |
| Natural History of Individuals With Immune System Problems That Lead to Fungal Infections Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 1200 | 2012-11-05 | 2026-08-24 |
Polyendocrinopathies, Autoimmune (3) · Aspergillosis, Allergic Bronchopulmonary (1) · Blastomycosis (1) · Candidiasis, Invasive (1) · Candidiasis, Vulvovaginal (1) · Coccidioidomycosis (1) · Histoplasmosis (1) · Invasive Fungal Infections (1) · Invasive Pulmonary Aspergillosis (1) · Job Syndrome (1) · Mycoses (1) · Pulmonary Alveolar Proteinosis (1)
Bacterial Infections and Mycoses (5) · Candidiasis (5) · Chronic Disease (5) · Dermatomycoses (5) · Disease Attributes (5) · Infections (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Skin Diseases (5) · Skin Diseases, Infectious (5) · Skin and Connective Tissue Diseases (5) · Immune System Diseases (4) · Mycoses (4) · Autoimmune Diseases (3) · Endocrine System Diseases (3)
Amphotericin B (1) · Rituximab (1) · ibrexafungerp (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Matinas BioPharma Nanotechnologies, Inc. (1) · Scynexis, Inc. (1) · University Hospital, Lille (1)
United States (4) · Austria (1) · France (1) · Germany (1) · Netherlands (1) · Pakistan (1) · South Africa (1) · Spain (1) · United Kingdom (1)
Alexandra Freeman, MD (1) · Christa S Zerbe, M.D. (1) · Michail S Lionakis, M.D. (1)
PMID 31095438, PMID 32557834, PMID 35699443, PMID 36875114
2017 (1)